Literature DB >> 23257529

The clinical characteristics of two anti-OJ (anti-isoleucyl-tRNA synthetase) autoantibody-positive interstitial lung disease patients with polymyositis/dermatomyositis.

Kei Kunimasa1, Machiko Arita, Takashi Nakazawa, Maki Tanaka, Kazuya Tsubouchi, Satoshi Konishi, Yasushi Fukuda, Mika Saigusa, Hiroaki Nakagawa, Satoshi Ubukata, Yohei Korogi, Takao Fujii, Tsuneyo Mimori, Tadashi Ishida.   

Abstract

We herein report the clinical and laboratory characteristics of two anti-OJ (anti-isoleucyl-tRNA synthetase) autoantibody-positive interstitial lung disease patients with polymyositis/dermatomyositis (PM/DM). We compared these characteristics with previously published findings. Previous reports and our present cases show that anti-OJ autoantibody-positive interstitial lung disease (ILD) patients with PM/DM lack the manifestations of Raynaud's phenomenon and sclerodactyly and show good prognoses and responses to glucocorticoid therapy. These results indicate that the presence of anti-OJ autoantibodies may be useful for predicting the prognosis of ILD and its clinical course in PM/DM patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23257529     DOI: 10.2169/internalmedicine.51.7452

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  7 in total

Review 1.  Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review.

Authors:  Michael Mahler; Frederick W Miller; Marvin J Fritzler
Journal:  Autoimmun Rev       Date:  2014-01-11       Impact factor: 9.754

Review 2.  Idiopathic inflammatory myopathies.

Authors:  Mazen M Dimachkie; Richard J Barohn; Anthony A Amato
Journal:  Neurol Clin       Date:  2014-08       Impact factor: 3.806

Review 3.  Management of Interstitial Lung Disease in Patients With Myositis Specific Autoantibodies.

Authors:  Christopher A Mecoli; Lisa Christopher-Stine
Journal:  Curr Rheumatol Rep       Date:  2018-04-10       Impact factor: 4.592

Review 4.  Myositis-associated interstitial lung disease: a comprehensive approach to diagnosis and management.

Authors:  Robert W Hallowell; Julie J Paik
Journal:  Clin Exp Rheumatol       Date:  2021-03-25       Impact factor: 4.473

5.  Significance of myositis autoantibody in patients with idiopathic interstitial lung disease.

Authors:  Ju Sun Song; Jiwon Hwang; Hoon-Suk Cha; Byeong-Ho Jeong; Gee Young Suh; Man Pyo Chung; Eun-Suk Kang
Journal:  Yonsei Med J       Date:  2015-05       Impact factor: 2.759

Review 6.  Efficacy and safety of mycophenolate mofetil in the treatment of rheumatic disease-related interstitial lung disease: a narrative review.

Authors:  Giulia Cassone; Marco Sebastiani; Caterina Vacchi; Gian Luca Erre; Carlo Salvarani; Andreina Manfredi
Journal:  Drugs Context       Date:  2021-01-15

7.  Novel case of anti-synthetase syndrome.

Authors:  Aniruddh Kapoor; Philip Vaidyan; Basmah Jalil; Chitra Upaluri
Journal:  Eur J Rheumatol       Date:  2018-06-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.